Frontlight ResearchEarly access
TerminatedNo phase
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
Key facts
- Who runs it
- Alpha Tau Medical LTD.
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 28 Aug 2019
- Ended
- 30 Nov 2023
- Type of study
- Interventional
- Treatments tested
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Record updated
- 18 January 2024
- Why it stopped
- Difficulty in recruiting patients
Who can take part
- Age
- 45 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (28)Hide the full registry criteria
Who can take part
- Subjects with histopathological confirmation of primary (or recurrent) invasive breast carcinoma and distant metastatic disease at diagnosis
- Target tumor size ≤ 3.0 cm (T1-2b category)
- Morphological type: invasive breast cancer
- Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-, Her2/neu+1), or Triple negative breast carcinoma
- Measurable disease according to RECIST v1.1
- Subjects over 45 years old
- Subjects' ECOG Performance Status Scale is < 2
- Subjects' life expectancy more than 6 months
- Platelet count ≥100,000/mm3
- International normalized ratio of prothrombin time ≤1.8
- Creatinine ≤1.9 mg/dL
- Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test
- Subjects are willing to sign an informed consent form
Who cannot take part
- Patients with pre-irradiation of the breast
- Patients undergoing immunosuppressive and/or systemic corticosteroid treatment
- Acute infection disease
- The presence of HIV, RW, HbsAg, HCV in the acute stage
- Serious competing (somatic) diseases incompatible according to the researcher with brachytherapy
- Mental illness
- Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)
- T4 category with skin involvement
- Regional lymph node metastases
- Ductal carcinoma in situ
- Inflammatory breast carcinoma
- Pregnancy or lactation
- Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
- High probability of protocol non-compliance (in opinion of investigator)
- Subjects not willing to sign an informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases
The group in the trial
- DaRT SeedsTreatment being tested
Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
Treatment: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
- Record updated
- 18 January 2024